Cannabis Research
THCP, Delta-8 and CBN: Why Cannabinoid Differences Matter

Key PointsTHCP showed substantial activity but its relative potency varied by outcome so no…
View more
- THCP showed substantial activity but its relative potency varied by outcome so no single multiplier holds.
- Ten CBN-treated mice died and the unresolved cause prevents confident route-specific safety conclusions.
- The experiments did not measure sleep so they cannot support CBN insomnia claims.
What does it mean to say one cannabinoid is stronger than another? Stronger at reducing a pain response, changing body temperature, or producing intoxication? Those questions sound similar, but they require different measurements. Answering them carefully could make cannabis research more useful and product descriptions more informative.
A new study accepted by the European Journal of Pharmacology examines that problem by comparing THCP, delta-8 THC, and cannabinol, better known as CBN, in mice.1 Researchers measured both biological effects and blood concentrations. THCP stood out for pronounced activity, while delta-8 THC and CBN generally produced weaker responses under the conditions tested.
The findings support a useful distinction: a cannabinoid can occur in tiny quantities in a plant and still have substantial biological effects. “Minor” describes abundance, not necessarily potency. The opportunity is to replace broad assumptions with evidence specific to each compound.
Why Cannabinoid Potency Needs More Than One Number
THCP, delta-8 THC, and CBN can interact with CB1 receptors, part of the signaling system involved in many familiar effects of delta-9 THC. Small structural differences between these compounds can affect receptor activity and how the body handles them.
Two scientific terms organize this problem. Pharmacodynamics describes what a compound does to the body. Pharmacokinetics describes what the body does to the compound, including absorption and elimination. Think of a delivery arriving at a building: the amount dispatched, the amount reaching the entrance, and what happens inside are separate questions.
Likewise, receptor affinity, or how readily a molecule binds to a receptor, cannot by itself establish the strength of a person’s experience. Blood exposure, tissue distribution, metabolism, and the outcome being measured also matter. A universal potency multiplier compresses those differences into a precision the evidence may not support.
How Researchers Compared THCP, Delta-8 THC and CBN
The team used adult C57BL/6 mice, examining single doses through intravenous injection, injection into the abdominal cavity, or oral administration, depending on the experiment. Separate experiments delivered delta-8 THC and CBN directly into the brain’s ventricular system to explore effects when compounds bypassed normal delivery barriers.
Researchers measured blood concentrations alongside body temperature, responses to a painful heat stimulus, and catalepsy, an abnormal persistence of a fixed posture. These are established animal measures of cannabinoid activity, but they do not directly measure a person’s subjective intoxication or clinical pain relief.
Several design details limit comparisons. The principal THCP dose-response experiments used intravenous administration, whereas delta-8 THC and CBN used abdominal injections. Delta-9 THC reference values came from earlier research rather than a fully matched comparison conducted alongside every experiment. THCP’s initial blood time-course experiment included males only, although later experiments included both sexes.
THCP Showed Strong Effects, With Important Differences
THCP produced dose-dependent catalepsy, lowered body temperature, and reduced responses to the painful stimulus. However, its apparent advantage over delta-9 THC depended on the measurement.
For catalepsy, the estimated dose producing half the modeled maximum response was similar to the historical delta-9 THC value. For temperature reduction and the pain-response test, the corresponding estimates were lower for THCP. These comparisons suggest substantial activity without supporting one multiplier for every effect.
Delivery also mattered. At the tested dose, estimated oral bioavailability was 6.8% for THCP, compared with a historical delta-9 THC value of 19%. Bioavailability describes exposure after one administration route relative to intravenous delivery. Lower oral bioavailability does not automatically mean a compound produces weaker effects, because exposure and biological activity are different properties.
| Finding | Meaning Within the Study | Key Limitation |
|---|---|---|
| THCP produced catalepsy, hypothermia, and reduced pain responses. | It showed substantial cannabinoid-like activity. | Relative potency varied by outcome; delta-9 THC comparisons used historical data. |
| Delta-8 THC and CBN generally showed limited activity. | Responses were weaker under the tested conditions. | Different administration routes limited comparison with THCP. |
| Estimated oral bioavailability was 6.8% for THCP, 21% for delta-8 THC, and 18% for CBN. | Oral exposure differed among the compounds. | These estimates came from single-dose mouse experiments. |
| Ten CBN-treated mice died. | The authors identified an unresolved toxicity signal. | The cause was unknown, and the manuscript inconsistently reports administration routes. |
Weaker Cannabinoid Responses Do Not Establish Safety
Delta-8 THC and CBN generally produced smaller effects in the main behavioral experiments. Neither produced significant catalepsy after abdominal injection at the tested doses. Some temperature and pain-response effects appeared, but they were limited or dependent on dose and sex.
That result needs a narrow interpretation. It does not establish that either compound is non-intoxicating at every dose. The authors acknowledge difficulty reconciling their relatively weak delta-8 THC findings with reports of its intoxicating effects in people.
The CBN mortality finding also requires attention. Nine males and one female died following treatment, with the cause unresolved. The methods attribute these deaths to intravenous dosing, while the discussion reports oral administration for two males. That inconsistency prevents confident route-specific reporting.
The researchers propose investigating metabolism as one possible explanation. It remains a hypothesis. These deaths neither establish the risk from a consumer CBN product nor justify dismissing the finding. Resolving the discrepancy and identifying the mechanism would make subsequent experiments more informative.
Why This Study Cannot Answer CBN Sleep Questions
The experiments did not measure sleep. Immobility, reduced pain responses, and lower temperature cannot establish whether a compound improves insomnia. MyCannabis’s explanation of sleep stages and circadian rhythms provides background on why sleep requires its own measurements.
Human research illustrates the distinction. A 2026 placebo-controlled CBN insomnia trial involving 20 adults found that neither tested dose significantly improved the primary outcome, time awake after initially falling asleep. The higher dose improved several secondary measures, offering reasons for further investigation without establishing broad effectiveness.
Meanwhile, Cochrane’s recent assessment of cannabis for insomnia found the available evidence too uncertain for reliable conclusions. Different formulations and outcomes make precision especially important.
Duration is another separate question. MyCannabis’s recent coverage of CBN tolerance and dependence research examines repeated exposure. A single-dose experiment cannot establish what changes after weeks of use.
Better Evidence Could Improve Cannabinoid Product Literacy
The broader implication is that cannabinoid research needs several measures rather than a single ranking. Potency tells researchers how much exposure produces a defined response. It does not establish how useful that response is, how long it lasts, or whether unwanted effects occur at similar exposures.
For example, if a compound reduces a laboratory pain response at a low dose, the next question is whether meaningful pain relief can occur without unacceptable impairment. This study cannot answer that clinical question, but it helps identify which comparisons deserve attention.
Three distinctions would make future findings easier to interpret:
- Identify the specific outcome behind every potency claim.
- Separate the administered dose from measured blood exposure.
- Distinguish findings about isolated cannabinoids from evidence about finished formulations.
That final distinction also matters when comparing labels. MyCannabis’s Canadian CBD sleep products buying guide helps readers distinguish formulations and additional ingredients. Such comparisons support product literacy; they do not demonstrate that a blend reproduces findings from an isolated-cannabinoid experiment.
The Next Step Is More Comparable Cannabinoid Research
The authors plan to examine concentrations in brain, liver, and fatty tissue, investigate the unexplained CBN deaths, and study repeated dosing. Those steps could help explain why blood levels and observed responses do not always move together.
A particularly useful next comparison would test cannabinoids under matched delivery conditions while measuring desired and unwanted effects over time. Human studies would then need to establish whether those patterns translate into meaningful outcomes. The promise of this work is greater specificity: clearer questions can produce evidence that makes cannabinoid claims easier to evaluate.
References:
1 Jones, A. M., Shogaaeldein, H. M. A., Zagzoog, A., Andres, R., Halter, K., Cabecinha, A., Waye, A., Abramovici, H., Streicher, J. M., & Laprairie, R. B. (2026). Assessment of Δ9-tetrahydrocannabiphorol (THCP), Δ8-tetrahydrocannabinol (Δ8-THC), and cannabinol (CBN) pharmacodynamics and pharmacokinetics across multiple routes of administration in the C57BL/6 mouse. European Journal of Pharmacology. Advance online publication. https://doi.org/10.1016/j.ejphar.2026.179538












